Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475199 | 1.00 | EPHX2 (0.33) | EPHX2DPP4DPP7GRM2GRM3 | |
| SCHEMBL2209199 | 0.80 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL2209193 | 0.80 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL16770030 | 0.80 | APLNR (0.37) | EPHX2GRM2GRM3 | |
| SCHEMBL18084397 | 0.77 | GRM2 (0.32) | EPHX2GRM2GRM3 | |
| SCHEMBL17933274 | 0.76 | MAPT (0.38) | — | |
| SCHEMBL31389897 | 0.74 | — | — | |
| SCHEMBL31759047 | 0.74 | TSHR (0.38) | EPHX2 | |
| SCHEMBL18084471 | 0.71 | HSD17B10 (0.42) | — | |
| SCHEMBL17933273 | 0.70 | UGT2B7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3383420-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seattle Genetics, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | EPHX2 3384/4885DPP4 1966/4885DPP7 1168/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | EPHX2 3384/4885DPP4 1966/4885DPP7 1168/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | EPHX2 3384/4885DPP4 1966/4885DPP7 1168/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | EPHX2 3384/4885DPP4 1966/4885DPP7 1168/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | EPHX2 3384/4885DPP4 1966/4885DPP7 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.